| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell and Tumor Biology |
Departments of 1 Neurology, 2 Pathology, 3 Oncology, and 4 Neurosciences, Johns Hopkins University School of Medicine; and 5 Kennedy Krieger Research Institute, Baltimore, Maryland
Requests for reprints: Roger Abounader, Kennedy Krieger Research Institute, 707 North Broadway, Suite 400-K, Baltimore, MD 21205. Phone: 443-923-2671; Fax: 443-923-2695; E-mail: abounader{at}kennedykrieger.org.
Embryonal central nervous system (CNS) tumors, which comprise medulloblastoma, are the most common malignant brain tumors in children. The role of the growth factor scatter factor/hepatocyte growth factor (SF/HGF) and its tyrosine kinase receptor c-Met in these tumors has been until now completely unknown. In the present study, we show that human embryonal CNS tumor cell lines and surgical tumor specimens express SF/HGF and c-Met. Furthermore, c-Met mRNA expression levels statistically significantly correlate with poor clinical outcome. Treatment of medulloblastoma cells with SF/HGF activates c-Met and downstream signal transduction as evidenced by c-Met, mitogen-activated protein kinase, and Akt phosphorylation. SF/HGF induces tumor cell proliferation, anchorage-independent growth, and cell cycle progression beyond the G1-S checkpoint. Using dominant-negative Cdk2 and a degradation stable p27 mutant, we show that cell cycle progression induced by SF/HGF requires Cdk2 function and p27 inhibition. SF/HGF also protects medulloblastoma cells against apoptosis induced by chemotherapy. This cytoprotective effect is associated with reduction of proapoptotic cleaved poly(ADP-ribose) polymerase and cleaved caspase-3 proteins and requires phosphoinositide 3-kinase activity. SF/HGF gene transfer to medulloblastoma cells strongly enhances the in vivo growth of s.c. and intracranial tumor xenografts. SF/HGF-overexpressing medulloblastoma xenografts exhibit increased invasion and morphologic changes that resemble human large cell anaplastic medulloblastoma. This first characterization establishes SF/HGF:c-Met as a new pathway of malignancy with multifunctional effects in human embryonal CNS tumors.
This article has been cited by other articles:
![]() |
Y. Li, F. Guessous, Y. Zhang, C. DiPierro, B. Kefas, E. Johnson, L. Marcinkiewicz, J. Jiang, Y. Yang, T. D. Schmittgen, et al. MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes Cancer Res., October 1, 2009; 69(19): 7569 - 7576. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Sikkema, S. H. Diks, W. F.A. den Dunnen, A. ter Elst, F. J.G. Scherpen, E. W. Hoving, R. Ruijtenbeek, P. J. Boender, R. de Wijn, W. A. Kamps, et al. Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery Cancer Res., July 15, 2009; 69(14): 5987 - 5995. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Provencal, D. Labbe, R. Veitch, D. Boivin, G.-E. Rivard, H. Sartelet, Y. Robitaille, D. Gingras, and R. Beliveau c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration Carcinogenesis, July 1, 2009; 30(7): 1089 - 1096. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Labbe, M. Provencal, S. Lamy, D. Boivin, D. Gingras, and R. Beliveau The Flavonols Quercetin, Kaempferol, and Myricetin Inhibit Hepatocyte Growth Factor-Induced Medulloblastoma Cell Migration J. Nutr., April 1, 2009; 139(4): 646 - 652. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, F. Guessous, C. DiPierro, Y. Zhang, T. Mudrick, L. Fuller, E. Johnson, L. Marcinkiewicz, M. Engelhardt, B. Kefas, et al. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy Mol. Cancer Ther., February 1, 2009; 8(2): 376 - 385. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. N. Kongkham, P. A. Northcott, Y. S. Ra, Y. Nakahara, T. G. Mainprize, S. E. Croul, C. A. Smith, M. D. Taylor, and J. T. Rutka An Epigenetic Genome-Wide Screen Identifies SPINT2 as a Novel Tumor Suppressor Gene in Pediatric Medulloblastoma Cancer Res., December 1, 2008; 68(23): 9945 - 9953. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Trapp, G. Kogler, A. El-Khattouti, R. V. Sorg, M. Besselmann, M. Focking, C. P. Buhrle, I. Trompeter, J. C. Fischer, and P. Wernet Hepatocyte Growth Factor/c-MET Axis-mediated Tropism of Cord Blood-derived Unrestricted Somatic Stem Cells for Neuronal Injury J. Biol. Chem., November 21, 2008; 283(47): 32244 - 32253. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Guerreiro, S. Fattet, B. Fischer, T. Shalaby, S. P. Jackson, S. M. Schoenwaelder, M. A. Grotzer, O. Delattre, and A. Arcaro Targeting the PI3K p110{alpha} Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and Migration Clin. Cancer Res., November 1, 2008; 14(21): 6761 - 6769. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Binning, T. Niazi, C. A. Pedone, B. Lal, C. G. Eberhart, K. J. Kim, J. Laterra, and D. W. Fults Hepatocyte Growth Factor and Sonic Hedgehog Expression in Cerebellar Neural Progenitor Cells Costimulate Medulloblastoma Initiation and Growth Cancer Res., October 1, 2008; 68(19): 7838 - 7845. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, F. Guessous, S. Kwon, M. Kumar, O. Ibidapo, L. Fuller, E. Johnson, B. Lal, I. Hussaini, Y. Bao, et al. PTEN Has Tumor-Promoting Properties in the Setting of Gain-of-Function p53 Mutations Cancer Res., March 15, 2008; 68(6): 1723 - 1731. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Reznik, Y. Sang, Y. Ma, R. Abounader, E. M. Rosen, S. Xia, and J. Laterra Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor Mol. Cancer Res., January 1, 2008; 6(1): 139 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takami, P. Kaposi-Novak, K. Uchida, L. E. Gomez-Quiroz, E. A. Conner, V. M. Factor, and S. S. Thorgeirsson Loss of Hepatocyte Growth Factor/c-Met Signaling Pathway Accelerates Early Stages of N-nitrosodiethylamine Induced Hepatocarcinogenesis Cancer Res., October 15, 2007; 67(20): 9844 - 9851. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mogi, M. Iwai, and M. Horiuchi New Paradigm for Brain Protection After Stroke Hypertension, April 1, 2006; 47(4): 642 - 643. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |